Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimization of Albuminuria-Lowering Therapies for Individual Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial.

NCT06094920 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT06094920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06094920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimization of Albuminuria-Lowering Therapies for Individual Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial.
Lead sponsor
University Medical Center Groningen
Phase
Phase 4
Overall status
Completed
Start date
July 29, 2024
Completion date
September 24, 2025
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

albuminuria, chronic kidney disease due to type 2 diabetes mellitus, chronic kidney disease stage3, chronic kidney disease stage4, chronic kidney diseases, ckd, ckd stage 3, ckd stage 4, diabetes, diabetes complications, diabetes mellitus, diabetes mellitus type 2 with proteinuria, diabetes mellitus, type 2